Signing of the Mammorisk partial asset contribution agreement by Predilife

On October 2, 2024, Predilife announced the signing of a partial asset contribution agreement for the spin-off of its MammoRisk test. The latter is recognized internationally, in particular thanks to the MyPeBS study, the results of which are expected in 2027. MammoRisk aims to personalize breast cancer screening, with the aim of reducing metastatic cases by 20% and mortality by the same amount in France.

To promote its development and increase its financial autonomy, Predilife has created a wholly-owned subsidiary, also called MammoRisk. The evaluation by Sorgem Evaluation in April 2024 valued the system at €207.3 million. The contribution procedure will be simplified in accordance with Article L.236-22 of the French Commercial Code. The contribution projects have been filed with the Registries of the Commercial Courts of Créteil and Nanterre.

Predilife hopes to gain access to additional financing while maintaining control of its subsidiary.